[A23-14] Finerenone (CKD stage 1 and 2) – Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2023
Project no.:
A23-14
Commission:
Commission awarded on 27.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Kidneys and urinary system
Adults with chronic kidney disease (stage 1 and 2 with albuminuria) associated with type 2 diabetes
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-15 | Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-69 | Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14 | Commission completed |
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.